Xeris Biopharma Holdings, Inc.

XERS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$621-$1,928-$9,220-$5,113
Dep. & Amort.$3,049$2,918$3,143$3,133
Deferred Tax$0$0$0$0
Stock-Based Comp.$7,643$5,008$4,443$3,595
Change in WC$0-$6,882-$9,241-$474
Other Non-Cash$7,119$1,066$844$834
Operating Cash Flow$18,432$182-$10,031$1,975
Investing Activities
PP&E Inv.-$363$13-$13-$220
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$10,236
Other Inv. Act.$292-$292$0$0
Investing Cash Flow-$71-$279-$13$10,016
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$830$0$0$0
Stock Repurch.-$9,336$7,998-$7,998-$166
Dividends Paid$0$0$0$0
Other Fin. Act.$13,850$0$4,861$564
Financing Cash Flow$13,850$942-$3,137$398
Forex Effect$0$0$0$0
Net Chg. in Cash$0$845-$13,181$12,389
Supplemental Information
Beg. Cash$59,285$58,440$75,744$63,355
End Cash$0$59,285$62,563$75,744
Free Cash Flow$18,069$10,044-$10,044$1,755